Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group-Reference-Cited by-同舟云学术

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group

Published:2015-08 Issue:2 Volume:138 Page:278-284
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Vergote Ignace,Debruyne Philip,Kridelka Frédéric,Berteloot Patrick,Amant Frédéric,Honhon Brigitte,Lybaert Willem,Leunen Karin,Geldhof Kurt,Verhoeven Didier,Forget Frédéric,Vuylsteke Peter,D'Hondt Lionel,Huizing Manon,Van den Bulck Heidi,Laenen Annouschka

Funder

Amgen Inc

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference25 articles.

1. First-line therapy in ovarian cancer trials;Thigpen;Int. J. Gynecol. Cancer,2011

2. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup;Bookman;J. Clin. Oncol.,2009

3. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N. Engl. J. Med.,2011

4. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

5. What is the role of dose-dense therapy?;van der Burg;Int. J. Gynecol. Cancer,2005

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ciprofloxacin Derivative‐Loaded Nanoparticles Synergize with Paclitaxel Against Type II Human Endometrial Cancer;Small;2023-07-31

2. Endometrial Cancer;Fundamentals of Cancer Detection, Treatment, and Prevention;2022-05-13

3. Management of Recurrent Ovarian Cancer;Advances in Diagnosis and Management of Ovarian Cancer;2022

4. Epithelial ovarian cancer: Review article;Cancer Treatment and Research Communications;2022

5. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer;Seminars in Cancer Biology;2021-12